ArticleKidney diseases (Basel, Switzerland)
Makorin Ring Finger Protein 1 Inhibits Cell Proliferation in Renal Angiomyolipoma via the ERK/MAPK Signaling Pathway.
Article in Kidney diseases (Basel, Switzerland). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Renal angiomyolipomas (AMLs) are clonal tumors formed by the abnormal differentiation of transformed renal progenitor cells. However, the cytogenetic and malignant transformations of renal AMLs require further investigation. Makorin ring finger protein 1 (MKRN1), a transcriptional co-regulator and E3 ubiquitin ligase, may act as a tumor regulator that mediates tumor biological processes. Although it is known as a prognostic marker of renal cell carcinoma, hepatocellular carcinoma, and pancreatic adenocarcinoma, its expression and function in renal AMLs remain unclear. Therefore, we aimed to investigate the expression and function of MKRN1 in AML cells. Methods: MKRN1 expression in AML tissues was evaluated by immunohistochemistry, Western blotting, and quantitative real-time PCR. To investigate the functional role of MKRN1 in AML, MKRN1 was overexpressed in AML cells, and cell proliferation was assessed using the Cell Counting Kit-8 assay. Proliferative activity was further confirmed by immunofluorescence staining of Ki-67. To elucidate the molecular mechanisms regulated by MKRN1, gene set enrichment analysis (GSEA) was performed on RNA sequencing data, and the identified signaling pathways were further validated by Western blotting analysis. Results: MKRN1 expression was significantly lower in renal AML tissues than in para-tumorous tissues ( Conclusion: This study demonstrates that MKRN1 mediates AML cell proliferation by regulating the ERK/MAPK signaling pathway. These findings suggest that MKRN1 plays a crucial role in AML progression and may serve as a potential diagnostic and therapeutic biomarker for AML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.